Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-04

Clinical Trial Update: Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis [Phase 2]

View source ↗

Summary

Phase 2 trial comparing dalbavancin to an active comparator for osteomyelitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dalbavancin (dalbavancin)

Snippet

Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc | Conditions: Osteomyelitis | Phase 2 | Status: COMPLETED | Results posted: 2019-01-04